Figure 1
Kaplan–Meier estimated curves of EFS (a, c, e) and OS (b, d, f) according to MYC/BCL2 co-expression considering all (a, b), naïve (c, d) and relapsed/refractory (e, f) DLBCL patients.
Figure 1 | Blood Cancer Journal
Kaplan–Meier estimated curves of EFS (a, c, e) and OS (b, d, f) according to MYC/BCL2 co-expression considering all (a, b), naïve (c, d) and relapsed/refractory (e, f) DLBCL patients.
